that protect ~50% of rhesus monkeys (RMs) challenged with simian immunodeficiency virus (SIV). Because human CMV (HCMV) causes disease in immunodeficient subjects, clinical translation will depend upon attenuation strategies that reduce pathogenic potential without sacrificing CMV's unique immunological properties. We demonstrate that "intrinsic" immunity can be used to attenuate strain 68-1 RhCMV vectors without impairment of immunogenicity. The tegument proteins pp71 and UL35 encoded by UL82 and UL35 of HCMV counteract cell-intrinsic restriction via degradation of host transcriptional repressors. When the corresponding RhCMV genes, Rh110 and Rh59, were deleted from 68-1 RhCMV (Rh110 and Rh59), we observed only a modest growth defect in vitro, but in vivo, these modified vectors manifested little to no amplification at the injection site and dissemination to distant sites, in contrast to parental 68-1 RhCMV. Rh110 was not shed at any time after infection and was not transmitted to naïve hosts either by close contact (mother to infant) or by leukocyte transfusion. In contrast, Rh59 was both shed and transmitted by leukocyte transfusion, indicating less effective attenuation than pp71 deletion. The T cell immunogenicity of Rh110 was essentially identical to 68-1 RhCMV with respect to magnitude, T EM phenotype, epitope targeting, and durability. Thus, pp71 deletion preserves CMV vector immunogenicity while stringently limiting vector spread, making pp71 deletion an attractive attenuation strategy for HCMV vectors.
INTRODUCTION
The betaherpesviruses human cytomegalovirus (HCMV) and rhesus cytomegalovirus (RhCMV) are ubiquitous in human and rhesus monkey (RM) populations, respectively (1, 2) . Although these viruses are specifically adapted to their respective host species, they share orthologous genomes and a remarkably similar biology, reflecting millions of years of host-viral co-evolution (3, 4) . Infection usually occurs in the first year of life and is asymptomatic in the vast majority of subjects, with viral replication and spread controlled by host immunity, particularly virus-specific T cell responses (5, 6) . At the same time, CMV uses complex immune evasion strategies to prevent host immunity from clearing the infection or inhibiting its ability to spread to new hosts, including super-infection of CMV + hosts, resulting in permanent infections with one or more viral strains (7) (8) (9) . CMV and their primate hosts thus establish a stable equilibrium characterized by (i) a low viral burden in infected individuals with mostly latent infection (albeit with occasional reactivation and sufficient shedding to maintain efficient host-to-host transmission) resulting in persistent infection and (ii) an extraordinarily high frequency of CD4 + and CD8 + CMV-specific T cells with a unique effector memory (T EM )-biased phenotype and function that contains the infection and thus tissue damage and disease (6, 10, 11) .
Although other viruses can establish persistent infection, the lifelong, high-frequency, tissue-based, T EM -biased T cell responses established by CMV are unique, which raised the possibility of exploiting CMV as a vaccine vector for other infectious diseases (12) (13) (14) . In particular, we hypothesized that recombinant CMV expressing heterologous inserts would preposition potent, effector-differentiated responses to a different pathogen in the portal of entry and sites of early spread of that pathogen. This early interception (before implementation of immune evasive programs) would potentially have superior efficacy for immune evasive pathogens than typical vaccineelicited memory T cell responses that require anamnestic expansion over many days, if not weeks, to mount peak effector responses in tissues (14) . We demonstrated that the cellular immune responses elicited by strain 68-1 RhCMV vectors expressing simian immunodeficiency virus (SIV) inserts intercept and completely control SIV replication in the first week after challenge in ~50% of vaccinated RMs, without anamnestic expansion of SIV-specific immune responses (15) (16) (17) . The residual infection in protected RMs was progressively cleared over weeks to months, ultimately leaving these RMs indistinguishable by virologic and immunologic criteria from vaccinated RMs that were never challenged (17) . RhCMV vectors with Mycobacterium tuberculosis (Mtb) inserts elicit analogous CD4 + and CD8 + T EM responses to Mtb, and RMs vaccinated with these vectors show a nearly 70% reduction in Mtb disease after Erdman strain challenge, with 40% of vaccinated animals showing no detectable granulomatous disease at all (18) .
These preclinical data support consideration of the possible development of CMV-vectored HIV and Mtb vaccines for use in people, creating an imperative to develop and test HCMV-based vectors in the clinic (19, 20) . However, clinical development of HCMVbased vectors for prophylactic use in healthy individuals will require a high standard of safety. Although HCMV does not cause overt disease in the vast majority of infections, the potential for symptomatic primary infection in HCMV-naïve individuals, and for serious disease in immunocompromised subjects or in mother-to-fetus transmission (21) , is sufficiently high to contraindicate the use of unmodified HCMV vectors in a prophylactic vaccine setting. We therefore sought to develop an attenuation strategy that would reduce or, if possible, eliminate the pathogenic potential of HCMV yet retain the unique, persistent immunogenicity, as well as the ability to super-infect CMV + individuals. Furthermore, it is preferable for clinical vectors to not be transmissible by close contact or even transfusion, so as to prevent unintentional infection of individuals for which vaccination might pose a safety risk.
Encouragingly, mouse CMV (MCMV) rendered unable to spread from initially infected cells nonetheless maintained strong cellmediated immunity, suggesting that viral dissemination may not be required for immunogenicity (22) (23) (24) . However, it remains unclear whether highly debilitated RhCMV or HCMV vectors can establish and maintain persistent secondary infections in monkeys or humans. The HCMV strain Towne, attenuated by serial in vitro passaging, seems to have lost its ability for persistent immune induction as indicated by steadily declining T cell responses (25) . In addition, chimeras of Towne and a fibroblast-adapted derivative of the primary isolate Toledo were unable to establish secondary infections in HCMV + individuals (26) , and the T cell responses elicited by these chimeras in HCMV − individuals did not display the CMV-typical T EM phenotype and declined over time (27, 28) . These data suggest that traditional attenuation strategies may yield suboptimal HCMV vectors that lose the ability to maintain persistent immune stimulation.
Here, we examine a new strategy for CMV attenuation based on exploiting host proteins that provide "intrinsic" immunity. This term describes cellular intrinsic defense mechanisms involving host proteins such as death domain-associated protein (DAXX), -thalassemia X-linked mental retardation protein (ATRX), BCL-associated factor 1 (BclAF1), and promyelocytic leukemia protein (PML) that combine to form nuclear ND10 bodies (29) . ND10 proteins repress transcription of viral immediate early (IE) genes, which are critical for early (E) and late (L) gene expression and genome replication (30, 31) . To counteract intrinsic immunity, herpesviruses encode proteins that eliminate or disperse ND10 components (32) . HCMV evades intrinsic defenses through viral tegument proteins released during viral entry, thus facilitating IE expression (33) . The tegument protein pp71, encoded by UL82, mediates the degradation of DAXX (34) (35) (36) and, together with UL35, BclAF1 (37) in the infected cell nucleus. Intrinsic immune repression of IE expression might enable the establishment and maintenance of latency by silencing viral genes needed for lytic replication (38) (39) (40) . Thus, by eliminating viral countermechanisms targeting intrinsic immunity, it might be possible for CMV vectors to maintain persistent infection and long-term immune stimulation while severely hampering lytic replication, cell-to-cell spread, and distant dissemination. To examine this possibility, we characterized the in vivo replication, spread, dissemination, and immunogenicity of RhCMV vectors lacking Rh110 and Rh59, the RhCMV orthologs of HCMV UL82 and UL35.
RESULTS

RhCMV pp71 mediates DAXX degradation and supports
RhCMV growth in vitro HCMV pp71 has two DAXX interaction domains that are required for localization of pp71 to ND10 bodies (41) , where pp71 dislocates ATRX and mediates the degradation of DAXX by the proteasome (38) . Although Rh110, the predicted RhCMV pp71 ortholog, shares 41% identity with HCMV pp71 (42) , these DAXX interaction domains are not conserved. Nevertheless, when RhCMV pp71 was expressed in telomerized rhesus fibroblasts (TRFs) under doxycycline (DOX) control, steady-state DAXX was reduced upon removal of DOX (Fig. 1A) . When we examined the localization of rhesus DAXX, ATRX, and PML by immunofluorescence, we observed punctate nuclear costaining of these proteins in the absence of pp71. Upon pp71 expression, both ATRX and DAXX no longer localized in punctate dots, whereas pp71 partially colocalized to PML bodies ( fig. S1 ). Thus, despite lacking canonical DAXX interaction domains, RhCMV pp71 degrades and displaces DAXX from PML bodies similar to HCMV pp71 (32) .
As reported for HCMV (31, 35, 36, 43, 44) , DAXX and BclAF1 were reduced during early times of infection with parental strain 68-1 RhCMV (68-1) compared to uninfected cells (Fig. 1B) [unless otherwise noted, all RhCMV constructs are based on bacterial artificial chromosome (BAC)-derived strain 68-1 (45) ]. This degradation was mediated by pp71 because DAXX abundance and, to some extent, BclAF1 abundance were restored in fibroblasts infected with 68-1 RhCMV lacking pp71 (Rh110) (Fig. 1B and fig. S2 , A and B). At the high multiplicity of infection (MOI) used in this experiment, deletion of pp71 did not affect the kinetics or expression of IE, E, or L proteins, similar to previous reports showing that DAXX repression of HCMV gene expression is overcome at high MOI (36, 43) . This growth defect could be reversed by knockdown of DAXX expression ( fig. S2C ), suggesting increased antiviral activity by DAXX being the main reason for the observed growth defect and consistent with increased IE expression reported for HCMV upon DAXX small interfering RNA (siRNA) treatment (36) .
pp71-deleted RhCMV could be recovered upon BAC transfection of fibroblasts without the need for complementation, and high-titer stocks could be generated in the absence of pp71 complementation. In contrast, UL82-deleted HCMV could only be grown in pp71-complementing cells (46) , and guinea pig CMV lacking the UL82 homolog could not be recovered unless complemented (47) . To determine the impact of pp71 deletion and complementation on viral growth in vitro, we compared 68-1 virus production upon infection of fibroblasts with RhCMV in which Rh110 had been replaced with SIVgag (Rh110/SIVgag) so that transcription was regulated by the native Rh110 promoter. Rh110/SIVgag was generated on complementing cells, which results in pp71 incorporation into the virus particle ( fig. S2D ), or without complementation ( −/− ). There was little or no growth impairment of complemented or uncomplemented Rh110/SIVgag at high MOI (1 and 0.1), whereas a 10-to 100-fold reduction of viral yield was observed at low MOI (0.01 and 0.001) (Fig. 1C) . In contrast, a 10-to 100-fold reduction in viral growth was reported for complemented or uncomplemented HCMV at high MOI and ~5-log reduction in viral growth at low MOI (46) , suggesting that abrogation of pp71 expression affects growth of RhCMV less severely than that of HCMV. Nevertheless, pp71 deletion reduced spreading of virus from infected cells to neighboring cells because the average plaque sizes of complemented and uncomplemented Rh110/SIVgag at day 7 post-infection at low MOI (0.001) were strongly reduced compared to 68-1 in TRFs but not in TRFpp71 (Fig. 1D) . Thus, although pp71 is not absolutely required for RhCMV growth in vitro, it substantially enhances the efficiency of viral spreading in fibroblast cultures.
Rh110 RhCMV is spread deficient in vivo but remains immunogenic for T cell responses
To examine whether deletion of pp71 would affect viral dissemination in vivo, we subcutaneously inoculated RhCMV-naïve RMs with 10 7 plaque-forming units (PFU) of 68-1 expressing SIVgag in the left arm and complemented Rh110-expressing SIVrev/tat/nef/int (rtni) in the right arm ( fig. S2A) . The viral constructs used in each of the in vivo experiments in this report are schematically depicted in fig. S3 . RMs were necropsied at 14, 21, or 28 days post-infection (dpi), and viral copy numbers were determined by ultrasensitive, nested quantitative polymerase chain reaction (qPCR) specific for SIVgag or SIVrtni sequences in multiple tissue samples (17, 48) . SIVgag-containing genomes were detectable in most tissues in the RMs necropsied at 14 dpi, with particularly high genome copy numbers observed at the site of inoculation and associated draining lymph nodes, the contralateral injection site, and salivary glands (Table 1A) , whereas genome copy numbers were progressively lower in RMs necropsied at 21 and 28 dpi, in keeping with progressive immune control of infection, but were still detectable in most tissues. In notable contrast, genomes for Rh110/ SIVrtni were barely detectable in the same tissues at 14 dpi and below detection limits in almost all tissues at 21 and 28 dpi (Table 1A) . Of note, similar frequencies of SIVgag-and SIVrtn-specific CD4 + and CD8 + T cell responses were measured in lymphoid and nonlymphoid tissues of all three RMs, with the possible exception of some tissues at 14 dpi where SIVgag-specific T cell responses were modestly higher ( fig. S4A ). Thus, deletion of Rh110 markedly limited the genome replication and dissemination of RhCMV during primary infection but had little to no effect on the initial development of vector-elicited, SIV-specific T cells.
The inability to detect Rh110/SIVrtni by ultrasensitive PCR at 4 weeks after primary infection could indicate that RhCMV lacking pp71 was unable to persist and thus might be unable to maintain immune stimulation. However, in two RhCMV-naïve RMs given 10 7 PFU of Rh110, the magnitude and kinetics of T cell responses to RhCMV IE1 and pp65a in peripheral blood mononuclear cells (PBMCs) and bronchoalveolar lavage (BAL) cell preparations were comparable to that of four RhCMV-naïve RMs inoculated with 10 7 PFU of 68-1 through 231 dpi (Fig. 2, A and B) . In contrast to 68-1, Rh110 was not shed in the urine of these monkeys at any time point (Fig. 2C) , confirming the in vivo attenuation of Rh110. Thus, despite marked inhibition of viral spread in vivo, the lack of pp71 did not affect viral immunogenicity in the first 7 months after primary infection.
A key feature of CMV vectors is their ability to overcome preexisting anti-CMV immunity, permitting the use of CMV vectors ) at MOI = 0.001. Plaques were analyzed at 7 dpi using phase microscopy, and plaque size was measured using Adobe Photoshop. Individual plaque sizes, as well as average (±SD) from one of two experiments, are shown. The Kruskal-Wallis (KW) test was used to determine the significance of differences between the three groups [P = 0.0002, left; P = not significant (NS), right], with the Wilcoxon rank sum test used to perform pairwise analysis if KW P values were ≤0.05; brackets indicate pairwise comparisons with two-sided Wilcoxon P ≤ 0.05. P ≤ 0.05 is considered statistically significant. regardless of previous CMV infection (7), which must be preserved in any attenuation strategy. To determine whether Rh110 retained this capability, we administered RhCMV-seropositive (RhCMV + ) RMs with 10 7 PFU of 68-1/SIVrtni (subcutaneously, right arm) and the same dose of complemented Rh110/SIVgag (subcutaneously, left arm) and monitored their dissemination by qPCR in tissues of RMs necropsied at 14, 21, or 28 dpi. As shown in Table 1B , preexisting immunity substantially reduced genome copy numbers of 68-1/SIVrtni in all tissues when compared to nonimmune RMs (Table 1A) , consistent with anti-CMV immunity profoundly limiting replication and dissemination of Rh110-intact 68-1 RhCMV. However, similar to seronegative RMs, Rh110 was not detectable or barely detectable in any tissues at 14 dpi, except for the inoculation site, and in the RMs necropsied at 21 and 28 dpi, this vector was below the limit of detection in all tissues. Again, SIVgag-and SIVrtn-specific CD4 + and CD8 + T cell responses were detectable in most tissues of all three RMs and were of comparable magnitude ( fig. S4B ), indicating that even in the setting of preexisting anti-CMV immunity, the development of RhCMV vector-elicited, insert-specific T cell responses was not compromised by the Rh110 deletion. We also compared the spread of uncomplemented Rh110 with pp71 complementation, which would provide the incoming vector with pp71 in its tegument and increase the efficiency of the first round of vector replication. At 14 dpi, both complemented Rh110/SIVgag and uncomplemented Rh110/SIVrtni were largely undetectable in tissues in two RhCMV + RMs (Table 1C) , confirming the profound spread deficiency of pp71-deleted vectors.
Persistent CMV infections, including infections with 68-1 RhCMV vectors, elicit and indefinitely maintain high-frequency T EM , likely reflecting continuous or frequently recurring antigen exposure (13, 15, 18, (49) (50) (51) . To determine whether, despite limited spreading, pp71-deficient RhCMV maintained T EM with the same phenotype and function as 68-1 in CMV-immune RMs, we co-inoculated four RhCMV + RMs with complemented Rh110/SIVrtni or 68-1/SIVpol-5′ so as to directly compare their immunogenicity in the same RM. 68-1/SIVpol-5′ was shed into urine at 28 dpi in all four RMs and found in all urine samples thereafter, as expected (7), whereas Rh110/SIVrtni was not detected in urine at any time point through 490 dpi ( fig. S5 ). Despite this notable difference, the average peak and plateau phase frequencies of SIVrtn-specific CD4 + and CD8 + T cells elicited by Rh110/SIVrtni in blood and BAL were similar, if not higher, than the corresponding SIVpol-specific T cell responses elicited by 68-1/SIVpol-5′ ( Fig. 3A and fig. S6 ). Moreover, the circulating SIVrtn-specific CD4 + and CD8 + T cell responses elicited by Rh110 displayed the same highly T EM -biased phenotype (CCR7 − , CD28 − ; Fig. 3B ) as 68-1 vector-elicited responses and overlapping patterns of cytokine production that were commensurate with the T EM phenotype [high tumor necrosis factor- (TNF-), interferon-γ (IFN-γ), and macrophage inflammatory protein 1 (MIP-1), and low interleukin-2 (IL-2); Fig. 3C ]. We also previously reported that 68-1 RhCMV vectors elicit CD8 + T cells that very broadly target highly unconventional epitopes restricted by either major histocompatibility complex class II (MHC-II) or MHC-E (52, 53) . This broad, unconventional epitope targeting is not affected by pp71 deletion (Fig. 3D ). Thus, the magnitude, durability, phenotype, cytokine synthesis function, and CD8 + T cell epitope targeting of Rh110-elicited SIV-specific T cell responses were essentially indistinguishable from that elicited by parental 68-1 RhCMV. We therefore conclude that, despite our inability to detect Rh110 in tissues 4 weeks after inoculation, pp71-deficient RhCMV persists in tissues at levels that support the maintenance of abundant, highly T EM -biased, RhCMV-and insert-specific T cells.
To confirm that Rh110 RhCMV vectors could be used repeatedly in the same RM, either to boost preexisting T cell responses or elicit new T cell responses to different inserts, we inoculated two RMs that had previously been vaccinated with Rh110/SIVrtni both with a second dose of Rh110/SIVrtni and with a different pp71-deleted vector expressing an SIVenv insert. As shown in Fig. 4A , this repeat, dual vaccination resulted in both a transient boosting of the SIVrtn-specific CD4 + and CD8 + T cell responses and the de novo induction of an SIVenv-specific CD4 + and CD8 + T cell response of similar magnitude. This outcome is essentially identical to the previously reported boosting and repeated de novo infection behavior of pp71-intact 68-1 RhCMV (15). Moreover, the magnitude of both the SIVrtn-and SIVenv-specific CD4 + and CD8 + T cell responses remained stable for at least 4 years ( Fig. 4A) , at which point immune monitoring was discontinued. Thus, pp71-deleted RhCMV vectors retain the unique ability of this vaccine platform to sequentially induce and maintain T cell responses to different antigens in the same host.
CMV vectors are T cell-targeted vaccines, and RhCMV vectors elicit few, if any, insert-specific antibodies (Abs) in RMs (15) (16) (17) (18) . However, these vectors have the potential to elicit/boost Ab responses to RhCMV itself, raising the question of whether Rh110 vectors differ from parental 68-1 vectors in this activity. To address this, we compared RhCMVspecific Ab responses in cohorts of RhCMV + RMs that were vaccinated with either a 68-1 (n = 16) or Rh110 (n = 14) RhCMV/SIV vector set composed of five vectors, each expressing one SIVmac239 insert (gag, env, rtn, pol-5′, and pol-3′) and subcutaneously administered at a dose of 5 × 10 6 PFU per vector. Abs to whole RhCMV viral lysates were measured by enzymelinked immunosorbent assay (ELISA) before and 4, 6, and 12 weeks after vaccination. As shown in fig. S7 , both cohorts showed a significant (P < 0.001), but transient, boost in Ab titers, the magnitude of which was not different between the monkeys vaccinated with Rh110 versus 68-1 vectors. Thus, when administered in a high-dose vaccination regimen, pp71-deleted RhCMV vectors were able to boost Ab responses to a similar degree as the parental 68-1 vectors.
To determine the extent to which pp71 deletion affects the minimal dose required for T cell immunogenicity, we first inoculated three cohorts of seropositive RMs (n = 3 each) with 10 To further refine the dose required for immunogenicity, we reinoculated the three RMs that had failed to respond to 10 2 PFU with 10 3 PFU Rh110/SIVgag, and for comparison, we inoculated all nine RMs with 10 1 PFU of 68-1/SIVpol-5′ (Fig. 4B ). Despite the extremely low dose of 68-1 administered, all nine RMs manifested SIVpol-specific CD4 + and CD8 + T cell responses, and at 10 3 PFU, Rh110/SIVgag also induced both CD4 + and CD8 + SIVgag-specific T cells. Because this experiment was conducted with Rh110 vectors grown on complementing cells, we also determined the minimal dose required for uncomplemented Rh110 while, at the same time, confirming the minimal effective dose for complemented Rh110. We directly compared the immunogenicity of three different Rh110 constructs in three RhCMV + RMs: (i) pp71-complemented Rh110/SIVenv at 10 3 PFU, (ii) uncomplemented Rh110/SIVgag at 10 3 PFU, and (iii) uncomplemented Rh110/SIVrtni at 10 4 PFU. As shown in Fig. 4C , the 10 3 PFU dose was immunogenic (elicited SIVenv-specific T cells) for the pp71-complemented Rh110/SIVenv vector but not for the uncomplemented Rh110/SIVgag vector. However, at the 10 4 PFU dose, the uncomplemented Rh110/SIVrtni vector was immunogenic, indicating that pp71 complementation provides a 1-log dose sparing.
No evidence for recombination of Rh110 RhCMV/SIV vectors with endogenous RhCMV
One concern with using CMV vectors in CMV + hosts is the possibility of recombination between the vector and the endogenous virus that would revert the attenuation. Such in vivo recombination has been reported for alphaherpesvirus vaccines and naturally circulating varicella zoster strains (54, 55) , and deep sequence analysis of primary HCMV isolates shows signs of past recombination events (56) . To investigate propensity for recombination with endogenous virus, we designed three vectors each carrying two SIV antigens as immunogenic markers in different parts of the RhCMV genome. In all three vectors, SIVenv replaced Rh110, whereas SIVpol-5′ replaced the coding sequence of three different RhCMV genes-Rh19, Rh107, and Rh192 (corresponding, respectively, to the HCMV RL11 gene family, UL78, and US12)-in different parts of the genome. Each gene locus was shown to support insert expression and to be dispensable for vector replication in vitro ( fig. S8 ). Any repair of Rh110 by homologous recombination would result in a virus that lacks SIVenv but retains SIVpol, and repair of Rh110 by other types of recombination would yield a pp71-intact vector with one or both of the SIV inserts included, any of which would likely be dissemination competent and therefore expected to appear in the urine over time. Upon inoculation of two RhCMV + RMs with each of the three recombinants, we observed de novo induction and long-term maintenance of CD8 + T cell (Fig. 5 , A to C) and CD4 + T cell ( fig. S9 , A to C) responses to both SIVenv and SIVpol, indicating "take" and persistence of all three vectors and functional expression of both inserts in each vector. In general, the magnitude of the SIVpol-and SIVenvspecific CD4 + and CD8 + T cell responses over >800 days of follow-up was similar in each RM (with the possible exception of modest reduction in the CD8 + T cell response to Rh107-regulated pol), suggesting that T cell immunogenicity is not highly dependent on promoter type or location in the RhCMV genome. Immunoblots of cocultures of viruses isolated from urine of all six RMs were consistently negative for SIV antigens over >800 days of observation (Fig. 5D) , suggesting that the Rh110 deletion was not repaired by recombination with endogenous virus in any of these RMs over a >2-year period.
Lack of Rh110 RhCMV/SIV vector transmission with close contact
Transmission of RhCMV is highly efficient, with essentially 100% of conventionally raised RMs becoming RhCMV + in the first year of life (2) . In keeping with this, we observed serial transmission of SIV-specific cellular immunity (using de novo SIV-specific T cell responses as a surrogate for vector transmission) from a 68-1/SIV vector-vaccinated dam to her newborn infant and then, after weaning, from the infant to a cohoused cagemate (Fig. 6A and fig. S10A ). In contrast, the nursing infants of five naturally RhCMV-infected dams inoculated with Rh110 vectors (10 6 PFU each of five different vectors expressing SIVenv, pol-5′, pol-3′, gag, and rtn) did not acquire SIV-specific CD4 + or CD8 + T cell responses to any insert, although in all five instances, de novo responses to RhCMV were observed, indicating that endogenous RhCMV was transmitted from mother to infant (Fig. 6, B to F, and fig. S10, occurs, the amount is insufficient to mediate transmission to even a highly susceptible naïve host over prolonged periods of close contact.
Attenuation analysis of Rh59 (UL35)-deleted RhCMV/SIV vectors
To determine whether the lack of viral dissemination, viral shedding, and hostto-host transmission of pp71-deleted vectors was unique to this deletion or extended to other viral proteins that counteract intrinsic immunity, we evaluated the attenuation resulting from deletion of Rh59, the homolog of HCMV UL35, which cooperates with pp71 to counteract the cellular restriction factor BclAF1 (37). Similar to deletion of UL82, deletion of UL35 results in a modest growth defect at low MOI of HCMV (57) . Rh59 was deleted from 68-1/SIVrtni, or the Rh59 open reading fame (ORF) was replaced with SIVgag ( fig. S11 ). Also similar to Rh110, we were able to recover both Rh59/SIVrtni and Rh59/SIVgag without the need for complementation. However, RhCMV lacking Rh59 showed a 10-to 100-fold reduction of viral yield at all MOIs tested (Fig. 7A) , suggesting that deletion of Rh59 affects viral replication even at high MOI. This growth defect was also reflected by reduced plaque size measured at 7 dpi (Fig. 7B ).
To evaluate Rh59 vector spread in vivo, we performed necropsies on three RhCMV + RMs at 14, 21, and 28 days after subcutaneous inoculation with 10 7 PFU of Rh59/SIVgag (right arm) and the same amount of 68-1/SIVrtni in the left arm. As shown in Table 2 , the genome copy numbers of Rh59/SIVgag were at or below detection limits in all tissues tested at all three time points, whereas 68-1/SIVrtni was detected at all time points in multiple tissues. As demonstrated for Rh110, SIVgag-specific CD4 + and CD8 + T cell responses in tissues at necropsy elicited by Rh59 were similar to the SIVrtn-specific responses elicited by 68-1 in the same RM ( fig. S12A ). Longitudinal analysis of Rh59 versus 68-1-elicited SIV-specific CD4 + and CD8 + T cells in blood (Fig. 7C ) and BAL ( fig. S12B ) further showed similar response magnitude and durability in two RMs over 250 days, suggesting that deletion of Rh59 did not affect vector immunogenicity despite substantially decreased dissemination in vivo.
Rh59, but not Rh110, RhCMV/SIV vectors are shed and transmitted upon leukocyte transfer
To further compare the relative attenuation of Rh110 and Rh59 in vivo, we first inoculated RhCMV + RMs with Rh59/SIVrtni and Rh110/SIVenv and then, 175 days later, inoculated these RMs with 68-1/SIVpol-5′ and Rh110 68-1.2/SIVgag. Compared to 68-1 RhCMV, 68-1.2 RhCMV displays broader cell tropism due to repair of Rh157.5 and Rh157.4 (homologous to the pentameric receptor complex subunits UL128 and UL130 in HCMV), as well as the antiapoptotic gene Rh61/60 (UL36 in HCMV) (58) . Rh110 68-1.2/SIVgag was thus generated to determine whether increased antiapoptosis activity and the ability to more efficiently infect nonfibroblast cells due to an intact pentamer would counter the attenuation resulting from pp71 deletion. All four vectors induced de novo, persistent CD8 + (Fig. 8A ) and CD4 + ( fig. S13A ) T cell responses to their respective SIV inserts in all four RMs that were similar in magnitude in all tissues ( fig. S13B ). In keeping with previous results, 68-1/SIVpol-5′ appeared in urine by 56 dpi (day 231 of the experiment) and at every subsequent time point, whereas Rh110/SIVenv was not detected in the urine at any time point through 742 dpi (Fig. 8B) . Similarly, Rh110 68-1.2 /SIVgag was not found in urine though 567 dpi (day 742 of the experiment), indicating that repair of the pentameric complex and antiapoptotic genes did not reverse the attenuation of pp71 deletion. However, in sharp contrast, Rh59/SIVrtni appeared in urine in one RM at 91 dpi, and in all RMs by 112 dpi, and was found in all subsequent urine samples (Fig. 8B) . Thus, despite the in vitro growth deficiency and strongly reduced in vivo dissemination, Rh59-deficient RhCMV was shed from infected RMs, albeit with a modest delay compared to 68-1 RhCMV. CMV can readily spread from infected individuals to naïve recipients by blood transfusion or bone marrow transplantation, likely from latent viral reactivation in myeloid lineage cells, particularly monocytes (59) (60) (61) . To more stringently compare the in vivo spread deficiency of Rh59 and Rh110, we adoptively transferred by intravenous infusion 8 × 10 6 or 19 × 10 6 bone marrow cells plus 30 × 10 6 peripheral blood leukocytes from two RMs inoculated with Rh59/ SIVrtni, Rh110/SIVenv, 68-1/SIVpol-5′, and Rh110 68-1.2/SIVgag to two naturally RhCMV-infected, but vector-naïve, RMs and then monitored these recipient RMs for induction of SIV-specific T cell responses indicating vector transmission (Fig. 8C) . SIVpol-and SIVrtn-specific T cell responses rapidly appeared in both RMs. The SIVpol-specific responses arising from transmission of the 68-1 vector peaked a week earlier than the SIVrtn-specific responses arising from transmission of the Rh59 vector, whereas SIVenv and SIVgag responses were never detected, consistent with a lack of transmission of both 68-1-and 68-1.2-derived Rh110 vectors. These data indicate either that Rh110 vectors were not present in the transferred cells or that these attenuated viruses were unable to reactivate from latency and disseminate despite being transferred in myeloid cells. These data indicate that the long-term in vivo attenuation afforded by deletion of Rh110 (pp71) is greater than that afforded by deletion of Rh59 (UL35).
DISCUSSION
The goal of this study was to identify a strategy that would enhance the safety of CMV-based vectors while maintaining the unique immunologic features that characterize the CMV vector platform, in particular the establishment and maintenance of high-frequency T EM in both CMV-naïve and naturally CMV-infected individuals.
Because it is very likely that the indefinite maintenance of T EM requires long-term Ag exposure provided by persistent viral infection (62), attenuation strategies that eliminate viral persistence would not be suitable for this purpose. In this regard, the replicationdeficient HCMV with in vivo-abrogated expression of IE1/2 and UL51 currently being developed as an HCMV vaccine (63) would not be expected to maintain high-frequency T EM with appropriate long-term functionality. Moreover, because it is very likely that the unique phenotype and function of CMV vector-elicited responses reflect the composite interaction of the virus' many immunomodulatory programs with the host immune system (64, 65) , attenuation strategies that interfere with these programs also run the risk of adversely affecting the quality of the CMV vector-elicited immune responses. For instance, we previously demonstrated that deletion of the gene region encoding RhCMV homologs of the MHC-I evasins US2-11 resulted in vectors that lost the ability to super-infect (7), whereas retention of natural killer cell-activating ligands by RhCMV ORF Rh159 (UL148) was required for primary infection (66) . Therefore, in planning our CMV vector attenuation strategy, we sought an attenuation approach that would downmodulate, but not eliminate, CMV vector infectivity by markedly reducing its capacity to spread from cell to cell upon lytic replication or reactivation but that would otherwise preserve its immunomodulatory capabilities and its ability to persist. Our goal was a stably attenuated vector that would be able to exceed the threshold required for persistent immunogenicity but would be sufficiently spread restricted such that the infection would be kept well below the level required to cause disease and, even more stringently, below the level necessary to transmit vector from one individual to another. We also sought to accomplish this goal with discrete, difficultto-reverse genetic modifications based on well-understood mechanisms of action at the molecular and cellular levels so as to avoid, as far as possible, unexpected off-target impacts on vector biology and function.
In view of these immunobiological and virological considerations, genetic deletion of viral tegument proteins such as pp71 that counter host intrinsic immunity was an attractive candidate attenuation strategy. First, attenuation based on deletion is much more difficult to reverse in vivo than attenuation based on point mutations or on adding attenuating genetic elements, especially with our strategy of replacing the pp71 coding sequence with the heterologous Ag. This strategy not only results in a more naturally regulated expression of the transgene than use of heterologous promoters but also eliminates the possibility of reversing vector attenuation by homologous recombination with endogenous virus.
Second, the host intrinsic immune mechanisms under consideration are highly conserved in mammals, and the relevant components, such as DAXX, are essential genes that are expressed in every cell type (29, 67) . These features increase the likelihood of successful translation from RMs to humans and reduce concerns that genetic heterogeneity in the human population would reduce the effectiveness of this strategy in subpopulations, potentially placing subgroups of individuals at higher risk for adverse events after vaccination. The universality of these mechanisms had led to them being proposed as a general approach to attenuate herpes viral vaccines and vectors (68) .
Third, the pattern of in vitro attenuation reported for pp71 HCMV-reduction in viral growth at low MOI but not high MOI (46)-also appeared to be advantageous for a T EM -targeted vaccine, as it suggested a relatively specific and early defect in viral infectivity that greatly reduces, but does not eliminate, the capacity for lytic, productive infection. pp71 deletion does not appear to irrevocably inactivate CMV or change its fundamental immunobiology but, rather, appears to place a barrier to the triggering of its lytic genetic program that limits viral production and subsequent cell-to-cell spread during initial infection or upon subsequent reactivation from latency. Some pp71 CMV-infected cells (perhaps those exposed to high MOI) might bypass this restriction and progress to lytic infection, but pp71-deleted progeny of those few cells that produce virus would be severely handicapped in their ability to productively infect new cells, potentially resulting in a smoldering, low-level infection that persists, but cannot efficiently expand or disseminate. Moreover, pp71 CMV may go directly into latency (38, 39) , potentially maintaining the capacity for subsequent insert expression either during latency or in response to reactivation stimuli and therefore providing for persistent or periodic Ag production and presentation from all infected cells, whether or not they are able to engage in productive infection (64) . These promising in vitro characteristics do not, however, indicate whether the degree to which a pp71 CMV vector would manifest the necessary balance between infectivity and persistence (needed for immunogenicity) and spread restriction (needed for safety) would be appropriate for optimal vector function. The level of spread of pp71 in vivo might be too high or too low, resulting in insufficient attenuation or insufficient immunogenicity, respectively. In this regard, the relatively modest in vitro attenuation of Rh110 vectors relative to their HCMV counterparts (46) , even at very low MOI, raised concern that the pp71 RhCMV vector design might be insufficiently attenuated in the RM model. However, this turned out not to be the case, as pp71-deleted 68-1 vectors showed a remarkable degree of in vivo attenuation relative to pp71-intact RhCMV based on strain 68-1. Whereas 68-1 RhCMV showed high-level replication at the site of inoculation (>10 9 genome copies/10 7 cell equivalents at day 14) and robust dissemination in primary infection, coinjected Rh110 was barely detectable with a high-sensitivity assay at 14 dpi and was essentially undetectable in tissues taken later. The numbers of Rh110 genome copies were so low in both primary and super-infection (with no difference between primary and superinfection, in contrast to 68-1) that it remains unclear whether there was any spread of Rh110 in vivo; the genome copies detected at day 14 might simply reflect the Rh110 genomes from the injected (high dose) inoculum and/or the virus produced within the cells infected by this inoculum. The robust attenuation of Rh110 was also supported by our findings that whereas 68-1 is readily shed in urine and efficiently transferred from RM to RM with close (motherto-infant) contact or blood cell transfusion, Rh110 was never found in urine and was not transferred from RM to RM with either close contact or cell transfer. These data may indicate that pp71 is essential for in vivo RhCMV infectivity such that Rh110 would be too attenuated for use as an effective vector. However, this concern is allayed by comparable 68-1 and Rh110 CD4 + and CD8 + T cell immunogenicity, even in the setting of super-infection. Moreover, as shown in the companion article, we demonstrate that Rh110 vectors show efficacy against viral challenge that is as good or better than 68-1 vectors (69).
The only clear immunologic difference between Rh110 and parental RhCMV vectors was the dose required to establish immunogenicity. Whereas 68-1 can establish fully immunogenic superinfection with 10 injected PFU, the (uncomplemented) Rh110 vector required 10 4 PFU to establish immunogenicity in RhCMV + RMs. This observation is consistent with the hypothesis that the primary defect of Rh110 is a reduction in its ability to spread from cell to cell. The lack of any shedding or transmission of Rh110 suggests that this vector never effectively seeds shedding sites, such as the salivary glands and kidneys, or long-term latency sites such as hematopoietic stem cells and their myeloid lineage progeny in the bone marrow and in the circulation (60, 61) . This, in turn, implies that robust CMV vector immunogenicity can be achieved and maintained with a local infection (sites of inoculation and draining lymph nodes) initiated by 10 4 PFU and, therefore, possibly involving only thousands of infected cells or fewer.
The magnitude of the SIV-specific T cell responses elicited by the different effective doses of Rh110, with or without complementation, and by the pp71-intact 68-1 RhCMV was similar, suggesting that a threshold level of vector infection and associated insert expression is required to trigger immunogenicity, but once this threshold is achieved, the magnitude of resultant immune response is dose independent. Because complemented Rh110 has pp71 in its tegument to facilitate the first round of replication, the comparison between 68-1 and uncomplemented Rh110 better reflects the effect of pp71 deletion on in vivo spread, indicating that pp71 deletion compromises vector spread by at least 1000-fold in vivo (10,000 PFU versus 10 PFU), a 10-to 100-fold higher deficit than the reduction of viral growth observed with low MOI in vitro.
The Rh59 (UL35)-deleted RhCMV vector, which showed an MOI-independent 1-to 2-log growth defect in vitro and a similar spread deficiency after in vivo inoculation as Rh110, did not show the same overall attenuation as Rh110, as Rh59 was both shed in urine and readily transferred to naïve RMs by leukocyte transfer. Thus, although UL35 is involved in countering the same intrinsic immune mechanism as pp71, the contribution of this protein to inactivating the host PML repressor complex would therefore appear to be less than pp71, at least for RhCMV. Alternatively, pp71 could support in vivo spread by countering additional host defense mechanisms. For instance, it was recently reported that pp71 of HCMV counters the innate immune signaling adaptor STING (70) . From a vaccine development standpoint, the biologic phenotype of Rh59 (UL35) RhCMV, though adequately immunogenic, is not satisfactorily attenuated for a primary CMV attenuation strategy.
Most of the Rh110 constructs analyzed in this study were based on BAC-cloned strain 68-1 (45), which shows CMV-typical signs of fibroblast adaptation including deletion of UL128 and UL130 homologous subunits of the tropism-determining pentameric receptor complex (Rh157.5 and Rh157.4), and a defect in the antiapoptotic UL36 homolog Rh60/61 (4, 71, 72) . These mutations are associated with reduced viremia, shedding, and transmission of 68-1 compared to low-passage RhCMV isolates (73) , and thus potentially contribute to the attenuation of Rh110. However, repair of the homologs of UL128, UL130, and UL36 in strain 68-1.2 (58) did not enable Rh110-deleted RhCMV to be shed or transmitted by transfusion. This observation suggests that increased surveillance by intrinsic immunity resulting from Rh110 deletion substantially increases the attenuation afforded by the other deletions (particularly pentameric complex ablation) that spontaneously occurred in 68-1 during tissue culture adaptation.
The low level of in vivo infection manifested by Rh110 reduces the likelihood of coinfecting the same cell as endogenous RhCMV and potential repair of the Rh110 deletion by recombination. Homologous recombination of a Rh110 vector in which the Ag insert replaces the Rh110 coding sequence with an endogenous RhCMV would be expected to yield a pp71-intact, Ag-less vector and a pp71-deleted, Ag-containing version of the endogenous RhCMV strain, not an insert-expressing wild-type vector with the potential to spread. Thus, such a recombination event would have no consequence for either the vaccine recipient or unvaccinated close contacts.
It is, however, theoretically possible that pp71 expression might be restored in Rh110-deleted RhCMV by nonhomologous recombination, leaving a spread-competent CMV that also expresses the vaccine insert. Although this would not subject the vaccine recipient to additional risk, because this individual already harbors wild-type CMV, it could lead to shedding and consequent transmission to unvaccinated close contacts of an insert-containing CMV vector. However, in experiments designed to detect Rh110 repair by either homologous or nonhomologous gene exchange, we saw no evidence of such attenuation reversal in six superinfected RMs followed over 800 days. These data suggest that if such Rh110-repairing recombination occurs at all, then it is likely to be a very infrequent event. We would also note that the most likely outcome of pp71 CMV vector coinfection with a wild-type CMV is complementation of the pp71 CMV virions, as reported for MCMV lacking essential genes (74) , which would increase their infectivity. However, because the vast majority of available target cells would not be infected, this enhancement, like complementation during in vitro production, would be lost in subsequent rounds of infection and therefore would not be expected to meaningfully reduce pp71 CMV vector attenuation.
Together, our data support the general conclusion that the indefinite maintenance of T cell immunity by CMV vectors can be uncoupled from viral spread within individual hosts and viral dissemination among hosts. A limitation of our study is that we only evaluated attenuated vectors in immunocompetent animals where RhCMV is nonpathogenic. Nevertheless, the results strongly suggest that the markedly reduced capacity to spread will also limit the ability of attenuated vectors to cause disease while preserving full CMV vector immunogenicity. Our findings in RhCMV are reminiscent of the finding in the mouse model where it was demonstrated that single-cycle MCMV viruses (i.e., viruses that replicate their genomes but are unable to generate infectious progeny) generated the MCMV-typical T EM inflation over time and protected against MCMV challenge (23, 24) , and are in contrast to findings in most other replication-defective viral vector systems in development (75) . Although, so far, this finding is limited to animal models, the fact that similar observations were made in both murine and rhesus models bodes well for the development of safe, HCMV-based vaccines for the human population. Moreover, the "pp71 deletion by insert replacement" design is a viable vector design strategy for initial assessment of attenuated HCMV vectors in humans. Given that UL82 (pp71)-deleted HCMV is more growth restricted in vitro than RhCMVRh110 (5-log versus 2-log reduction relative to 68-1 at low MOI) (46) , it is likely that a HCMVUL82 vector will be, if anything, more attenuated in humans than Rh110 in RMs, offering an extra margin of safety at the possible expense of requiring a higher dose for immunogenicity.
MATERIALS AND METHODS
Study design
The objective of this study was to evaluate the impact of viral attenuation by deletion of RhCMV genes that, when present, counteract host immune responses. In vitro studies were performed with life-extended primary rhesus fibroblasts to determine the impact of viral gene deletions on host cell protein expression and viral growth. The number of independent experiments and the number of replicates per experiment are indicated in the figure legends. Animal studies were approved by the Institutional Animal Care and Use Committee. To minimize the number of animals used in these experiments, most were designed with the goal to generate qualitative rather than quantitative comparisons with nonattenuated vectors. Because we observed highly consistent results among the two to four animals per group, these low numbers were sufficient to determine whether attenuated viral vectors lack viral shedding, viral transmission, and recombination with endogenous virus while maintaining the ability to reinfect and elicit as well as maintain unconventionally restricted T cell responses. Furthermore, most key observations, e.g., lack of shedding, and all immunological parameters were independently observed in multiple experiments, whereas others, such as lack of spontaneous transmission, were independently confirmed by distinct experimental designs. To obtain quantitative comparisons with nonattenuated vectors, such as measurements of genome copy numbers or the determination of the minimal immunogenic dose, animal numbers were minimized by including internal controls, i.e., animals were co-inoculated with nonattenuated vectors. Primary data are reported in data file S1.
Statistical analysis
We used nonparametric testing to determine differences between groups. In comparisons of two groups only, we used two-sided Wilcoxon rank sum tests with  = 0.05 to detect differences between the groups. In comparisons of more than two groups, we used the Kruskal-Wallis rank sum test to detect any differences between groups with  = 0.05. If any differences were detected, we performed post hoc two-sided Wilcoxon rank sum tests with  = 0.05 on the pairwise differences between groups. No multiplicity adjustments were performed for post hoc analyses. All statistical analyses were performed using R (v. 3.2.2).
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